JIC
JAZZ icon

Johnson Investment Counsel’s Jazz Pharmaceuticals JAZZ Stock Holding History

Johnson Investment Counsel’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.32M Buy
17,581
+87
+0.5% +$15.2K 0.03% 221
2025
Q4 		$2.97M Sell
17,494
-3,660
-17% -$561K 0.02% 238
2025
Q3 		$2.79M Buy
21,154
+319
+2% +$38.3K 0.02% 248
2025
Q2 		$2.21M Buy
20,835
+45
+0.2% +$4.89K 0.02% 284
2025
Q1 		$2.58M Buy
20,790
+1,000
+5% +$130K 0.02% 242
2024
Q4 		$2.44M Sell
19,790
-1,100
-5% -$130K 0.02% 244
2024
Q3 		$2.33M Buy
20,890
+160
+0.8% +$17.5K 0.02% 256
2024
Q2 		$2.21M Buy
20,730
+3,890
+23% +$428K 0.02% 254
2024
Q1 		$2.03M Buy
16,840
+4,444
+36% +$544K 0.02% 271
2023
Q4 		$1.52M Sell
12,396
-700
-5% -$87.4K 0.02% 303
2023
Q3 		$1.7M Buy
13,096
+110
+0.8% +$14.7K 0.02% 273
2023
Q2 		$1.61M Buy
12,986
+2,646
+26% +$356K 0.02% 283
2023
Q1 		$1.51M Buy
+10,340
New +$1.53M 0.02% 283

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Johnson Investment Counsel's JAZZ Position: Q1 2026 in Review

Johnson Investment Counsel increased its Jazz Pharmaceuticals (JAZZ) stake by 0.5% in Q1 2026, buying an estimated $15.2K and bringing the position to 17,581 shares worth $3.32M. The position accounts for 0.03% of the portfolio, ranked #221.

Johnson Investment Counsel first reported a position in JAZZ in Q1 2023 and has held it in 13 quarters since. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Johnson Investment Counsel held 17,581 shares of Jazz Pharmaceuticals worth $3.32M as of Q1 2026.
  • Johnson Investment Counsel bought 87 Jazz Pharmaceuticals shares in Q1 2026, an estimated $15.2K.
  • Jazz Pharmaceuticals made up 0.03% of Johnson Investment Counsel's portfolio in Q1 2026, its #221 holding.
  • Johnson Investment Counsel first reported a position in Jazz Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Johnson Investment Counsel's 13F filing for Q1 2026, filed 4 May 2026.